FindTrial
Sign In

Study on the additional antihypertensive benefit of Sacubitril Valsartan Sodium in the treatment of primary aldosteronism

Study on the additional antihypertensive benefit of Sacubitril Valsartan Sodium in the treatment of primary aldosteronism

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062845
Enrollment
Unknown
Registered
2022-08-20
Start date
2022-08-20
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

patients with primary aldosteronism:Sacubitril Valsartan Sodium 100-200 mg/day

Sponsors

Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. Diagnosis of primary aldosteronism.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Patients with other secondary hypertension diseases; 3. Severe heart and liver dysfunction; 4. Serum creatinine > 265 umol/L, serum potassium > 5.5 mmol/L; 5. Taking diuretics or stopping diuretics for less than 4 weeks; 6. Other serious diseases (considered not suitable for screening by the investigator).

Design outcomes

Primary

MeasureTime frame
blood pressure;serum potassium;Renin;Aldosterone;Natriuretic peptide;blood glucose;C peptide;—

Countries

China

Contacts

Public ContactSu Xin

The Second Xiangya Hospital of Central South University

suxin71@csu.edu.cn+86 13808457300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026